TOGETHER… the Regulus team is leading the way in the discovery and development of microRNA therapeutics.
Dysregulated microRNA expression is a key factor in many complex multi-factoral diseases, including inflammatory disease, fibrosis, metabolic disease and cancer. microRNA therapeutics are oligonucleotides that modulate the function of microRNAs, correcting the imbalance of gene expression and associated cellular pathways to treat a broad range human disease.
microRNAs are members of a large class of non-coding RNAs of approximately 22 nucleotides in length that regulate most genes in the genome. A single microRNA can target and regulate up to hundreds of genes, each of which is involved in biological networks or pathways.
Regulus was formed in September 2007 by Alnylam Pharmaceuticals (NASDAQ:ALNY) and Isis Pharmaceuticals, now Ionis Pharmaceuticals (NASDAQ:IONS) and has continued to build upon its thought leadership, knowledge base, and intellectual property to become the leader in microRNA therapeutics.
Regulus Therapeutics is located in La Jolla, California and is led by a seasoned executive team and board of directors, with proven expertise in corporate management, business operations, drug discovery and development. Regulus’ scientific advisory board consists of world-class scientists and several of the foremost authorities in the field of microRNA research.
Together, we are confident that we have assembled the assets, strategic partners, scientific talent and corporate team to maintain our research, intellectual property and thought leadership in the creation of novel, first-in-class medicines through microRNA science.